Sanofi (NASDAQ:SNY) Given Average Rating of “Buy” by Analysts

Sanofi (NASDAQ:SNYGet Rating) has received a consensus rating of “Buy” from the eleven analysts that are currently covering the stock, reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $95.33.

Several equities research analysts recently commented on SNY shares. UBS Group cut their price target on shares of Sanofi from €122.00 ($131.18) to €121.00 ($130.11) and set a “buy” rating on the stock in a research note on Friday, April 8th. Barclays lifted their target price on Sanofi from €90.00 ($96.77) to €105.00 ($112.90) in a research report on Thursday, April 14th. Credit Suisse Group lifted their price target on Sanofi from €96.00 ($103.23) to €105.00 ($112.90) in a research report on Monday, March 28th. Morgan Stanley boosted their price objective on Sanofi from €110.00 ($118.28) to €112.00 ($120.43) in a research note on Friday. Finally, Stifel Nicolaus assumed coverage on shares of Sanofi in a research report on Monday, February 28th. They set a “buy” rating on the stock.

Shares of NASDAQ SNY traded down $0.60 during midday trading on Friday, hitting $54.63. 26,846 shares of the company’s stock were exchanged, compared to its average volume of 1,989,875. The firm’s fifty day simple moving average is $52.65 and its 200-day simple moving average is $51.06. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.44 and a quick ratio of 1.03. The company has a market cap of $138.06 billion, a PE ratio of 18.66, a P/E/G ratio of 1.23 and a beta of 0.55. Sanofi has a twelve month low of $46.92 and a twelve month high of $58.10.

Sanofi (NASDAQ:SNYGet Rating) last released its quarterly earnings data on Friday, February 4th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. Sanofi had a net margin of 16.52% and a return on equity of 24.61%. The company had revenue of $11.43 billion for the quarter, compared to analysts’ expectations of $11.78 billion. Equities analysts anticipate that Sanofi will post 4.17 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of SNY. Boston Partners acquired a new position in Sanofi in the 3rd quarter valued at $221,371,000. Point72 Asset Management L.P. boosted its holdings in shares of Sanofi by 77.9% in the third quarter. Point72 Asset Management L.P. now owns 2,508,305 shares of the company’s stock valued at $120,925,000 after acquiring an additional 1,098,676 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Sanofi during the third quarter worth about $35,639,000. Clark Capital Management Group Inc. purchased a new position in Sanofi during the third quarter worth about $30,293,000. Finally, Goldman Sachs Group Inc. lifted its position in Sanofi by 29.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,227,680 shares of the company’s stock valued at $111,607,000 after purchasing an additional 506,752 shares during the period. Hedge funds and other institutional investors own 12.65% of the company’s stock.

Sanofi Company Profile (Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Featured Articles

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.